Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors such as OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. The proceeds from this financing will support Angitia’s robust pipeline of novel and differentiated treatments for serious musculoskeletal diseases.
Advancing Innovative Treatments for Musculoskeletal Conditions
Angitia is currently advancing two bispecific antibodies, AGA2118 and AGA2115, which target sclerostin and DKK1, respectively. These candidates are being developed for the treatment of osteoporosis and osteogenesis imperfecta (OI). Additionally, the company is working on AGA111, a biologic designed to promote spinal fusion in patients suffering from degenerative disc disease. This innovative pipeline reflects Angitia’s commitment to addressing significant unmet medical needs in the musculoskeletal disease space.
Strategic Partnerships and Future Growth
The successful Series C financing not only enhances Angitia’s financial position but also underscores the confidence of prominent investors in the company’s vision and potential. With the backing of leading investment firms, Angitia is well-positioned to accelerate the clinical development of its promising therapies and make a meaningful impact in the treatment of musculoskeletal diseases.-Fineline Info & Tech
